Assisted human reproduction has undergone extraordinary developments, but with a possible slowdown in the recent past.
This reduction in progress is rooted in several distinct causes: a markedly unfavorable economic situation caused by a shortening in the practical duration of patents; a greater severity of control bodies supervising the authorization of product licenses, stricter ethical requirements for clinical studies; and marked increases in costs associated with conducting randomized controlled trials (RCT) to evaluate new procedures or treatments.
Such difficulties can prevent young researchers from accessing funding for their ideas, because public grants cannot meet the costs necessary for developments or companies cannot finance ideas instead of products.
In the present scenario, procedures driven by meta-analyses triumph and suppress novel ideas for the betterment of the human condition.
Meta-analysis experts rise to leadership positions in medicine and those intuitive talents – which are needed more than ever for the advancement of medical science – are lost.
The conference will take stock of our medical discipline and provide a much-needed update on new products and ideas
that impact on reproductive medicine and surgery.
